FDA clears Inqovi plus venetoclax for newly diagnosed AML

The FDA has approved Inqovi, the oral fixed-dose combination of decitabine and cedazuridine from Taiho Oncology, for use with venetoclax in adults with newly diagnosed acute myeloid leukemia who are age 75 or older or have comorbidities that make them ineligible for intensive induction chemotherapy. The approval was announced May 13, 2026, and gives this patient group the first fully oral combination regimen cleared in the U.S. for frontline treatment. FDA said the decision was based on Study ASTX727-07, a single-arm trial in 101 patients, in which 42 patients achieved complete remission, for a complete remission rate of 41.6%, with a median time to remission of two months. (fda.gov)

Why it matters: For veterinary professionals, this is a human oncology development rather than an animal health one, but it’s still relevant as a signal in the broader shift toward oral cancer regimens that can reduce infusion-center burden and potentially make treatment more manageable for patients and caregivers. FDA’s approval also expands Inqovi beyond its earlier U.S. indications in myelodysplastic syndromes and chronic myelomonocytic leukemia, and the review was conducted under Project Orbis, underscoring the continued regulatory interest in faster pathways for oncology combinations. (fda.gov)

What to watch: Watch for the updated U.S. prescribing information, real-world uptake, and any additional data on durability, safety management, and how widely clinicians adopt an all-oral frontline AML option. (fda.gov)